Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System
← catalyst calendarSponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,173actual
Sites
48
Countries
Australia, Austria, Belgium +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-24 | actual | When the study began enrolling |
| Primary completion | 2025-10-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-15 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atrial Fibrillation
Intervention
- Device: FARAPULSE Pulsed Field Ablation system
Primary outcome
what the primary-completion date above is the date OFPrimary Effectiveness Endpoint
measured 12 monhts
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed